Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PhRMA CEO Castellani Brings Trade Group Leadership, CEO Management Skills To Job

This article was originally published in The Pink Sheet Daily

Executive Summary

Business Roundtable CEO John Castellani will succeed Billy Tauzin as head of PhRMA, and plans to focus on "implementation, improvement and innovation."

You may also be interested in...



U.K. Pharma Trade Group ABPI Taps Corporate Communications Exec As Next CEO

Stephen Whitehead trades finance hot seat to become chief executive of the Association of the British Pharmaceutical Industry.

U.K. Pharma Trade Group ABPI Taps Corporate Communications Exec As Next CEO

Stephen Whitehead trades finance hot seat to become chief executive of the Association of the British Pharmaceutical Industry.

Avandia Day Two Might Be Same Old Song Even With Broken RECORD

There may be more at stake for FDA, and the pharmaceutical industry in general, in how the advisory committees interpret the RECORD trial than there is for Avandia itself.

Related Content

Topics

UsernamePublicRestriction

Register

PS070888

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel